Hims & Hers Health’s CEO Andrew Dudum sold more than $33 million worth of company stock in the biggest insider transaction since the company went public four years ago https://t.co/A3GT0yKfZn ...

Core Insights - Hims & Hers Health, Inc. operates at the intersection of digital health and consumer wellness, utilizing a vertically integrated telehealth platform for personalized, subscription-based care [1][2] - The company emphasizes accessibility, personalization, and scalability, leveraging data from millions of clinical interactions to refine its offerings and enhance patient engagement [2][3] - Hims & Hers plans to expand internationally into markets such as the U.K., Germany, and Canada, while focusing on AI-driven personalization to meet evolving patient expectations [3] Company Overview - Hims & Hers provides a wide range of health services, including sexual health, dermatology, and weight loss, supported by nearly 1,500 licensed providers [1][2] - The service model combines direct-to-consumer approaches with integrated provider consultations, pharmacy services, and app-based tools for tailored treatment plans [1][7] - Subscription revenue is a key component of Hims & Hers' business model, ensuring predictable income streams and fostering deeper patient retention [2] Financial Performance - Hims & Hers shares have increased by 106.7% year to date, significantly outperforming the industry growth of 17.8% [6] - The Zacks Consensus Estimate for Hims & Hers' 2025 earnings per share indicates a 137% improvement from 2024 [8] - The company's forward 12-month price-to-sales ratio is 4.2X, lower than the industry average of 5.6X but higher than its three-year median of 2.3X [10] Earnings Estimates - The current quarter consensus estimate for earnings per share is $0.12, with projections of $0.14 for the next quarter and $0.64 for the current year [11] - Year-over-year growth estimates show a 100% increase for the current quarter and a 137.04% increase for the current year [11]

To join the Hims class action, go to https://rosenlegal.com/submit-form/?case_id=40578 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent ...

Core Viewpoint - A class action lawsuit has been filed against Hims & Hers Health, Inc. for allegedly making false and misleading statements regarding its business practices and partnerships, particularly concerning the promotion of Wegovy® and its collaboration with Novo Nordisk [1][3][4]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased Hims securities between April 29, 2025, and June 23, 2025, with a deadline of August 25, 2025, for investors to apply as lead plaintiffs [1]. - The complaint alleges that Hims engaged in deceptive practices by promoting illegitimate versions of Wegovy®, which posed risks to patient safety [3]. - It is claimed that the company's positive statements about its business and prospects were materially misleading due to undisclosed risks regarding its collaboration with Novo Nordisk [3][4]. Group 2: Allegations Against Hims - The complaint specifies that Hims failed to disclose that its communication with Novo Nordisk was not as beneficial as portrayed, potentially jeopardizing the long-term collaboration for access to Wegovy [4]. - It is alleged that Hims misrepresented the approval of its compounded semaglutide products by Novo Nordisk, which could mislead investors about the company's product offerings [4]. - The lawsuit highlights that Hims made false statements regarding the availability of branded Wegovy alongside its compounded products, which could mislead users and investors about the company's market position [4].

Core Viewpoint - Hims & Hers Health has faced significant stock declines due to lower revenue expectations from its personalized GLP-1 weight-loss medication and legal challenges stemming from a terminated partnership with Novo Nordisk [1][2][4]. Financial Performance - The company's total revenue for Q2 2025 was $545 million, reflecting a 7% sequential decline [3]. - Revenue from compounded GLP-1 weight-loss drugs decreased to $190 million from $230 million in the previous quarter [3]. - Revenue per subscriber fell to $74 from $84, attributed to the off-boarding of some GLP-1 subscribers [3]. Legal Issues - Hims & Hers is facing a securities class action lawsuit related to misleading statements made between April 29 and June 23, 2025 [5]. - The lawsuit alleges deceptive promotion and selling of illegitimate versions of Wegovy®, which jeopardized patient safety and led to the termination of the partnership with Novo Nordisk [6]. - Following the announcement of the partnership termination on June 23, 2025, Hims' stock price dropped over 34% [6]. Business Model Shift - The company has shifted its business model after the FDA ended mass compounding of certain weight-loss drugs, moving towards personalized, smaller-dose versions [4]. - Hims previously touted its collaboration with Novo Nordisk but lost it due to regulatory concerns regarding its practices [4].

Core Viewpoint - A class action securities lawsuit has been filed against Hims & Hers Health, Inc. alleging securities fraud that affected investors between April 29, 2025, and June 23, 2025 [1][2]. Group 1: Lawsuit Details - The complaint claims that Hims & Hers Health, Inc. engaged in deceptive practices by promoting and selling illegitimate versions of Wegovy®, which jeopardized patient safety [2]. - It is alleged that this conduct posed a significant risk of terminating the Company's collaboration with Novo Nordisk [2]. - The lawsuit asserts that the positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 25, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving in this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - Hims & Hers Health, Inc. is facing allegations of deceptive practices related to the promotion and sale of illegitimate versions of Wegovy®, which may jeopardize its collaboration with Novo Nordisk and mislead investors about the company's prospects [2]. Group 1: Allegations and Legal Action - The class period for the allegations is from April 29, 2025, to June 23, 2025 [2]. - Allegations include that Hims engaged in deceptive promotion and selling of illegitimate versions of Wegovy®, risking patient safety [2]. - The complaint suggests that the misleading statements from the company could lead to the termination of its collaboration with Novo Nordisk [2]. Group 2: Shareholder Information - Shareholders who purchased shares during the class period are encouraged to register for potential lead plaintiff appointment by August 25, 2025 [3]. - Registration allows shareholders to receive updates through a portfolio monitoring software regarding the case's status [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and illegal business practices [4]. - The firm is dedicated to ensuring companies adhere to responsible business practices and good corporate citizenship [4]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [4].

Core Viewpoint - Hims & Hers Health is experiencing significant revenue growth and expanding its subscriber base, despite volatility in its stock price and challenges in the weight loss segment [1][4][6]. Financial Performance - In Q2, Hims & Hers reported a revenue increase of 73% year-over-year, reaching $544.8 million, which was at the high end of its forecast but below analyst expectations [4][10]. - Monthly online revenue per subscriber rose by 30% to $74, and the total number of subscribers increased by 31% to nearly 2.44 million [4][10]. - Adjusted EBITDA surged to $82.2 million, a 109% increase from the previous year, and adjusted EPS was $0.17, exceeding analyst expectations [8][10]. Subscriber Growth - The number of customers using at least one personalized subscription grew by 89% to 1.5 million, making up over 60% of the subscriber base [5]. - The company noted a 170% increase in subscribers using personalized treatment plans for multiple conditions, reaching over 500,000 [5]. Marketing and Expenses - Marketing expenses increased by 50% to nearly $218 million, accounting for 40% of revenue, down from 46% a year ago, indicating improved efficiency [7][10]. - The gross margin was reported at 76%, reflecting a decrease of 500 basis points year-over-year [10]. Future Outlook - Hims & Hers maintains its 2025 revenue forecast of $2.3 billion to $2.4 billion, representing growth of 56% to 63%, and adjusted EBITDA guidance of $295 million to $335 million [10][11]. - For Q3, the company projects revenue between $570 million and $590 million, with adjusted EBITDA of $60 million to $70 million [11]. - The company is planning international expansion, starting with Canada and targeting Europe, Latin America, and Asia in the coming years [11][12]. Growth Opportunities - Hims & Hers is expanding into new areas, including hormonal health, which is expected to contribute to its long-term revenue goals of $6.5 billion by 2030 [12]. - The company continues to see strong growth across various health categories, despite challenges in the weight loss segment [13]. Valuation - The stock trades at a forward P/E ratio of around 55 based on 2025 analyst estimates, with a PEG ratio under 0.6, indicating potential undervaluation [14]. - The price-to-sales multiple is 5.5 times 2025 estimates, suggesting reasonable pricing given the high gross margins of the subscription business [14].

Core Insights - Hims & Hers is experiencing rapid revenue growth but is currently facing a legal battle that poses risks to its future performance [1][4] - The company's stock has seen a significant decline of 17% this week and is down 25% from its all-time highs, despite a remarkable 400% increase over the past five years [1][2] Financial Performance - In Q2 2025, Hims & Hers reported a 73% year-over-year revenue growth, exceeding $500 million, driven by a 30% increase in total subscribers and a 30% rise in spending per active subscriber [2] - The company has achieved $2 billion in trailing revenue, marking an increase of over 1,000% in the last five years, solidifying its position as a leading telehealth provider [6] Legal Challenges - Hims & Hers is embroiled in a legal dispute with Novo Nordisk, stemming from allegations of selling knockoff weight loss drugs after a partnership ended due to disagreements [3][4] - The company is accused of illegally selling patented weight loss drugs at a discount now that the shortage has resolved, raising concerns among investors about the potential impact on future revenue and profitability [3][4] Market Position - Hims & Hers has made significant market share gains in the telehealth sector, particularly in the online provision of drugs and medical treatments [6] - Despite its strong growth trajectory, the ongoing legal issues may deter potential investors from buying the stock at its current dip [7][8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Hims & Hers Health, Inc. stock is from April 29, 2025, to June 23, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by August 25, 2025 [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [3]. - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Hims & Hers made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy [4]. - Specific claims include that Hims misrepresented the nature of its collaboration with Novo and the offerings available to its subscribers [4]. - The lawsuit asserts that when the true details were revealed, investors suffered damages [4].